Executive Director, Biometrics

Denise Trone is Executive Director, Biometrics at Avenzo Therapeutics. She has over 25 years of experience in Phase 1 through Phase 4 clinical trials and has deep expertise in oncology clinical development.

Prior to Avenzo, she served as Executive Director at Turning Point Therapeutics which was subsequently acquired by Bristol Myers Squibb (BMS) in August 2022. At Turning Point Therapeutics/BMS, she helped lead the Biostatistics and Statistical Programming Team to develop and secure NDA approval of AUGTYRO™ (repotrectinib).

Prior to joining Turning Point Therapeutics/BMS, Ms. Trone was the Senior Director, Biostatistics at Ignyta (acquired by Roche/Genentech in 2018) where she contributed to the development of ROZLYTREK™ (entrectinib). She has also held similar positions in Biostatistics at Ambit Biosciences (subsequently acquired by Daiichi Sankyo) where she contributed to the development of Vanflyta™ (quizartinib), Biogen/Idec, and Statprobe.

Ms. Trone holds an M.S. in Biostatistics from San Diego State University, a B.S. in Statistics from the University of California, Berkeley, and a Certificate in Clinical Trials Design and Management from University of California, San Diego.